NCT07581860

Not Yet Recruiting

Growth Hormone Resistance of Beta-cells

University of Missouri-Columbia Source

Compare

Other study identifiers

Sponsor study identifier

2111127-C

Study Type

observational

Estimated enrollment

10

Locations

1 country

Sites

1

Timeline

Study Start

August 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

September 1, 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

September 1, 2030

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: not yet recruiting
Estimated enrollment: 10 participants
Study completion date: September 1, 2030
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
May 5, 2026
Actual (reported)
First Posted
May 12, 2026
Actual (reported)
Study Start
August 1, 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
September 1, 2028
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
September 1, 2030
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: August 6, 2026
Status Verified: May 2026
Last Update Submitted: August 3, 2026

Conditions

Healthy Impaired Fasting Glucose (IFG)Impaired Glucose Tolerance (Prediabetes)Obesity & Overweight

Outcome Measures

Primary Outcomes (1)

Beta-cell function
Insulin secretion rate in relationship to plasma glucose
before and 7 days after rhGH administration

Study Arms (2)

Impaired fasting glucose

Impaired glucose tolerance

Eligibility Criteria

Age18 Years - 59 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

Sampling MethodNon-Probability Sample

Study Population

The study population will consist of lean and obese people ages 18-59 with impaired fasting glucose or impaired glucose tolerance.

You may qualify if:

body mass index \>18.5kg/m2 and \<45.9kg/m2

Sponsors & Collaborators

University of Missouri-Columbia
Otherlead

Study Sites (1)

University of Missouri School of Medicine

Columbia, Missouri, 65212, United States

Study coordinatorCONTACT573-884-6852 ahmc4@health.missouri.edu

MeSH Terms

Conditions

ObesityOverweightGlucose IntolerancePrediabetic State

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperglycemiaGlucose Metabolism DisordersMetabolic DiseasesDiabetes MellitusEndocrine System Diseases

Study Officials

Bettina Mittendorfer
University of Missouri-Columbia
PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Coordinator

CONTACT

573-884-6852 ahmc4@health.missouri.edu

Vasavi Shabrish

CONTACT

v.shabrish@missouri.edu

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Senior Associate Dean for Research; Professor, Medicine & Nutrition; NextGen Director of Clinical and Translational Sciences Unit

Study Record Dates

First Submitted

May 5, 2026

First Posted

May 12, 2026

Study Start

August 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

NCT07853898

Effects of Pistachios on Postprandial Metabolic Responses in Adults With Overweight or Obesity

Not ApplicableRecruiting

NCT07298915

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

Phase 3Not Yet Recruiting

NCT07592572

A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants

Phase 1Completed

NCT07316816

Stanford Pediatric Healthy Weight Index

Not ApplicableRecruiting

NCT07728383

A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

Phase 4Recruiting

NCT07698145

Changes in Body Composition Including Muscle With Anti-Obesity Medications, Both With and Without Exercise

Not ApplicableRecruiting

impaired fasting glucose \>/= 100mg/dL, \</= 126mg/dL or impaired glucose tolerance on 75g oral glucose tolerance test (blood glucose 140 to 199mg/dL at two-hours)

You may not qualify if:

pregnant, planning to become pregnant during the study, or breastfeeding
current diagnosis or history of type 1 or type 2 diabetes
use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
history of bariatric surgery
known, uncontrolled hypothyroidism
history of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
current cancer or cancer that has been in remission less than 5 years
first degree relative with type 1 diabetes
evidence of anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day
greater than 3% weight loss within three months of screening or engaged in regular (\>/= 3 days per week), continuous moderate- or high-intensity exercise of \>/= 30 min duration
mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent

Contact the study team to confirm eligibility.

September 1, 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

September 1, 2030

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

August 6, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing: Will share
Time Frame: 5 years after completion of the study

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07581860
Data provider: ClinicalTrials.gov
Source updated: 2026-08-06
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:40:27 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Impaired fasting glucose

Impaired glucose tolerance

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations